IMMX•Immix Biopharma priced an underwritten offering of 11,363,637 shares at USD 11 each, with expected gross proceeds of USD 125 million before discounts, commissions and expenses.
Immix Biopharma priced an underwritten offering of 11,363,637 common shares at USD 11.00 per share. The company expects gross proceeds of USD 125 million before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about Sept. 30, 2026, subject to customary conditions; net proceeds are earmarked for NXC-201 development, working capital and general corporate purposes. J.P. Morgan is sole book-running manager.
